A study to evaluate the real-world effectiveness of benralizumab on asthma exacerbations and OCS use in patients with severe eosinophilic asthma with available blood eosinophil lab measures and those who switched from omalizumab or mepolizumab
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Benralizumab (Primary) ; Corticosteroid
- Indications Asthma; Eosinophilia
- Focus Therapeutic Use
- Acronyms ZEPHYR 2
Most Recent Events
- 14 Nov 2022 Results assessing real-world effectiveness of benralizumab on asthma exacerbations and NP-related outpatient and oral corticosteroid (OCS) use in severe eosinophilic asthma patients comorbid nasal polyps, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
- 19 Oct 2022 Results assessing long-term (for up to 24 months of follow-up) effectiveness of benralizumab in patients with severe eosinophilic asthma, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
- 28 Feb 2022 Results (n=1292) presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology